Analysis10k / Blog
EN한국어ES
Reverse DCF · CI

What CI's Stock Price Is Really Betting On

The short answer

At today's price, Cigna's stock implies roughly -2.8% to -1.0% annual free-cash-flow growth for the next ten years — essentially flat to declining — while the company's actual FCF grew 8.6% a year and revenue grew 12.1% a year over the past four years.

The conclusion

At its current price, CI implies roughly -2.8% annual FCF growth for the next 10 years (WACC 9%) — essentially flat or slightly declining.

Cigna's actual FCF growth has averaged +8.6% a year over the past 4 years; revenue grew +12.1% a year over the same span.

Verdict: the market is pricing in stagnation or decline — a striking gap from Cigna's own recent track record The required growth rate is negative to roughly flat across every reasonable discount-rate assumption tested (8-12%), while Cigna has actually grown FCF 8.6% a year and revenue 12.1% a year over the past four years. This is one of the more pessimistic market expectations this site has found — the price essentially assumes Cigna's cash flow stops growing, or even shrinks slightly, for a full decade. That gap is worth investigating directly: recent PBM rebate regulation, the FTC settlement, and rising medical cost ratios, all covered in the snapshot and story pieces above, may already be priced in as reasons for skepticism.

-2.8% to -1.0% needed vs. 8.6% actual free-cash-flow growth

Market's ask (WACC 9%)
-2.8%
4-yr FCF CAGR
+8.6%
4-yr revenue CAGR
+12.1%

Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021 and FY2025 (FCF grew from $6.04B to $8.39B; revenue from $174.1B to $274.9B, both over 4 years).

How the discount rate changes the answer

Required growth by discount rate: 8% gives -4.8%, 9% gives -2.8%, 10% gives -1%, 12% gives 2.3%-4.8%8%-2.8%9% (base)-1%10%2.3%12%
Discount rate (bottom) vs. the growth the price then requires.
Required 10-year FCF growth by discount rate (WACC)
WACCRequired growth
8%-4.8%
9% (base case)-2.8%
10%-1.0%
12%+2.3%

Across every discount rate tested, the required growth rate stays at or below the low single digits — nowhere close to Cigna's actual 8.6% FCF pace. This conclusion is unusually insensitive to the discount-rate assumption: no reasonable WACC choice pushes the required rate anywhere near what Cigna has actually delivered.

What would change Cigna's negative-growth answer

  • Using 2025's standalone FCF ($8.39B) instead of trailing-twelve-month FCF ($9.11B) as the base nudges the required growth rate up slightly, from -2.8% to -1.7% at a 9% discount rate — health insurers' first-half cash flow tends to run seasonally weaker due to rising receivables, which the TTM figure smooths out.
  • Narrowing net debt to only long-term debt (excluding short-term borrowings) would lower net debt further, pushing the required growth rate even lower — implying an even more pessimistic market view.
  • Lowering the terminal growth rate from 2.5% to 2.0% would modestly raise the required growth rate, since the discounting effect would compound more heavily over the projection period.

The math behind -2.8% to -1.0%

Inputs, sources, model assumptions, and the calculation
  • Share price$276.08 — stockanalysis.com, Aug 31, 2026 close
  • Shares outstanding264,240,486 — 10-Q Q2 FY2026 cover page, Jul 24, 2026
  • Market cap$72.95B — price × shares (calculated)
  • Trailing-twelve-month FCF$9.11B — FY2025 FCF ($8.39B: $9.60B operating cash flow minus $1.21B capex) plus 1H FY2026 FCF ($0.15B) minus 1H FY2025 FCF (-$0.58B)
  • Total debt$31.46B — 10-K FY2025 balance sheet (Dec 31, 2025): $0.59B current + $30.87B long-term
  • Cash and equivalents$7.68B — 10-K FY2025 balance sheet
  • Net debt$23.79B — calculated
  • Discount rate (WACC)9% base case (8%/10%/12% tested)
  • Terminal growth rate2.5% — long-run GDP-level assumption

Normalization check: the 3-year average FCF (2023-2025) is $9.20B; FY2025's standalone figure ($8.39B) is -8.8% below that average — within the ±40% threshold, so no adjustment was strictly required. Trailing-twelve-month FCF ($9.11B) was used as the representative figure instead, to correct for first-half seasonality typical of a health insurer's cash flow.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt).

Historical CAGR check: 4-yr FCF CAGR (2021→2025) = ($8.39B ÷ $6.04B)^(1/4) − 1 = 8.6%. 4-yr revenue CAGR = ($274.9B ÷ $174.1B)^(1/4) − 1 = 12.1%.

Limits of the CI number

This number is a starting point, not an answer
  • This isn't a fair-value price target — it only shows what the current price already assumes.
  • Change the discount rate or the FCF base, and the answer moves somewhat, though the broad conclusion (a very low or negative required growth rate) holds across the range tested — see the sensitivity table above.
  • A negative required growth rate doesn't necessarily mean the stock is "cheap" — it may simply reflect that the market has already priced in real risks (PBM rebate regulation, medical cost inflation, large-customer concentration) covered in the snapshot and story pieces above.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Any investment decision, and its outcome, is your own responsibility.
Built from Cigna's 10-K filings (FY2021, FY2025) and 10-Q (Q2 FY2026), plus a web search for the current share price (stockanalysis.com, Aug 31, 2026). This tells you where to dig deeper — it is not a buy or sell signal.

What we'd watch next

These three checks would show whether this read is holding up. They are prompts for your own follow-up, not predictions.

  • Negative-growth answerThe price implies -2.8% to -1.0%, against 8.6% actual FCF growth.
  • Regulatory outcomeA ban on PBM rebates would test this. Follow policy.
  • Cash flow durabilityA striking gap suggests the price expects trouble. Ask what.

How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.

Frequently asked questions

What growth rate does CI's stock price assume?

At today's price, Cigna's stock implies roughly -2.8% annual free-cash-flow growth for the next ten years at a 9% discount rate — essentially flat to slightly declining cash flow.

How does that compare to Cigna's actual growth?

Cigna's actual free cash flow grew 8.6% a year over the past 4 years, and revenue grew 12.1% a year over the same span — both far above what the current price requires.

What share price was used for this analysis?

This analysis used $276.08, as of the Aug 31, 2026 close.